Tharimmune (NASDAQ:THAR) Issues Earnings Results

Tharimmune (NASDAQ:THAR) announced its quarterly earnings data on Tuesday. The company reported ($2.02) earnings per share for the quarter, Zacks reports.

Tharimmune Stock Performance

Tharimmune stock traded down $0.04 during midday trading on Thursday, reaching $1.40. The company’s stock had a trading volume of 3,588 shares, compared to its average volume of 353,467. The business has a 50-day moving average price of $1.75 and a 200-day moving average price of $2.12. Tharimmune has a 52 week low of $1.28 and a 52 week high of $7.46.

Analyst Upgrades and Downgrades

THAR has been the subject of several recent analyst reports. Rodman & Renshaw started coverage on shares of Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW upgraded shares of Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).